To investigate whether the expression level of METTL3 affects the therapeutic effect of combination therapy in NSCLC, we constructed METTL3 overexpression and knockdown cell lines (Fig. 4A-B). The gene discussed is METTL3; the disease is non-small cell lung carcinoma.